Marksans Pharma Limited has informed that a current Good Manufacturing Practice (cGMP) inspection was conducted by the US FDA at the 2nd manufacturing facility of the company located at Verna Industrial Estate, Verna, Goa, India from 3 -7 November 2025.

The said inspection concluded with Zero Form 483 observation.

Mark Saldanha, Managing Director said, “The successful outcome of the cGMP inspection by the US FDA is a testament to our ongoing commitment to product quality and regulatory compliance.”